Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Removed Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-18T13:45:53.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Version update from v3.4.3 to v3.5.0; study details, eligibility criteria, and outcomes remain unchanged.
    Difference
    0.1%
    Check dated 2026-03-21T00:52:20.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Revision 3.4.3 was added and 3.4.2 was removed. No study details or interactive elements appear to be altered.
    Difference
    0.1%
    Check dated 2026-03-06T18:20:45.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and v3.4.1 was removed. This appears to be a maintenance/version update that does not modify study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:22:38.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Revision update: v3.4.1 added, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T13:34:07.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page adds a 'Show glossary' option and updates metadata labels: 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. The previous labels were 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-29T06:40:56.000Z thumbnail image

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.